Pharma BD Deal Intelligence

Amgen Inc. / DISCO Pharmaceuticals AG

2026 · Licensing/Option · $618M · Complete

DISCO Pharmaceuticals entered an exclusive license agreement with Amgen to advance novel therapeutic candidates against a cancer cell-surface target mapped by DISCO's proprietary surfaceome platform, with small cell lung cancer and other solid tumors as the focus. Amgen receives exclusive global rights to develop and commercialize the resulting programs. DISCO is eligible for up to USD 618M in total payments plus royalties.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Amgen Inc. deals